van der Aa Maaike A, Pukkala Eero, Coebergh Jan Willem W, Anttila Ahti, Siesling Sabine
Comprehensive Cancer Centre, Stedendriehoek Twente, Enschede, The Netherlands.
Int J Cancer. 2008 Apr 15;122(8):1854-8. doi: 10.1002/ijc.23276.
With respect to cervical cancer management, Finland and the Netherlands are comparable in relevant characteristics, e.g., fertility rate, age-of-mother at first birth and a national screening programme for several years. The aim of this study is to compare trends in incidence of and mortality from cervical cancer in Finland and the Netherlands in relation to the introduction and intensity of the screening programmes. Therefore, incidence and mortality rates were calculated using the Cancer Registries of Finland and the Netherlands. Data on screening intensity were obtained from the Finnish Cancer Registry and the Dutch evaluation centre at ErasmusMC-Rotterdam. Women aged 30-60 have been screened every 5 years, in Finland since 1992 and in the Netherlands since 1996. Screening protocols for smear taking and referral to the gynaecologist are comparable. Incidence and mortality rates have declined more in Finland. In 2003, age-adjusted incidence and mortality in Finland were 4.0 and 0.9 and in the Netherlands 4.9 and 1.4 per 100,000 woman-years, respectively. Excess smear use in the Netherlands was estimated to be 24 per 1,000 women during a 5-year interval compared to 121 in Finland. The decline in mortality in Finland seems to be almost completely related to the screening programme whereas in the Netherlands it was initially considered to be a natural decline. Differences in risk factors might also play a role: the Netherlands has higher population density and higher percentages of immigrants and (female) smokers. The greater excess smear use in Finland might also have affected incidence.
在宫颈癌管理方面,芬兰和荷兰在相关特征上具有可比性,例如生育率、初育年龄以及多年来的全国筛查计划。本研究的目的是比较芬兰和荷兰宫颈癌发病率和死亡率的趋势与筛查计划的引入及强度之间的关系。因此,使用芬兰和荷兰的癌症登记处数据计算发病率和死亡率。筛查强度数据来自芬兰癌症登记处和鹿特丹伊拉斯姆斯医学中心的荷兰评估中心。30至60岁的女性每5年接受一次筛查,芬兰自1992年起,荷兰自1996年起。涂片采集和转诊至妇科医生的筛查方案具有可比性。芬兰的发病率和死亡率下降幅度更大。2003年,芬兰年龄调整后的发病率和死亡率分别为每10万女性年4.0和0.9,荷兰为4.9和1.4。据估计,荷兰每1000名女性在5年期间涂片使用过量人数为24人,而芬兰为121人。芬兰死亡率的下降似乎几乎完全与筛查计划有关,而在荷兰,最初认为是自然下降。风险因素的差异也可能起作用:荷兰人口密度更高,移民和(女性)吸烟者的比例更高。芬兰涂片使用过量情况更严重也可能影响了发病率。